Question

Some of the first functions to decline during this process are IL-2 production and ex vivo killing abilities. For 10 points each:
[10m] Name this process during which persistent viral or tumor-mediated antigenic stimulation of T cells causes attenuation of their effector functions. Unlike anergy, high expression of Tox is associated with this process.
ANSWER: T cell exhaustion [accept CD8+ T cell exhaustion or CD4+ T cell exhaustion; accept word forms of exhaust in place of “exhaustion”]
[10e] In the setting of HCV or HBV infection, higher values of this quantity correlate to more severe T cell exhaustion. NAAT tests for HIV measure this quantity that is given in RNA copies per milliliter.
ANSWER: viral load [or viral burden; or viral titre or viral titer; accept peak viremia]
[10h] Tumors-mediated T cell exhaustion represents a major limit to this form of therapy that can currently treat relapsed or refractory multiple myeloma, follicular lymphoma, and acute lymphoblastic leukemia.
ANSWER: CAR-T therapy [or chimeric antigen receptor T-cell therapy; accept adoptive cell therapy or ACT; prompt on chimeric antigen receptors or CARs or chimeric immunoreceptors; prompt on cancer immunotherapy]

Back to bonuses

Data

TeamOpponentPart 1Part 2Part 3Total
Chicago BUC Berkeley A010010
Chicago CFlorida B010010
Claremont ANYU A0000
Columbia AWUSTL B0000
Cornell AJohns Hopkins A010010
Duke AMIT A010010
Florida AColumbia B010010
Harvard AChicago A1010020
Imperial ANorth Carolina A010010
Maryland AMinnesota A010010
McGill AOhio State A001010
Michigan APenn State A010010
Northwestern AMinnesota B010010
Penn AVanderbilt A0000
Purdue AIndiana A010010
Rutgers AHouston A010010
Stanford ABrown A10101030
Toronto AWUSTL A1010020
UC Berkeley BRutgers B0000
Virginia AIowa State A010010
Yale ATexas A0101020